TELO
Telomir Pharmaceuticals, Inc.
0.5950
+0.02 (+2.73%)
52w low 0.5450
1.58 high
4.8% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | -- | 5.07M | 1.15M | 2.13M | 1.04M | 1.76M | |
| R&D | -- | 42.84K | 759.52K | 1.30M | 467.80K | 444.67K | |
| SG&A | -- | 5.03M | 386.95K | 838.47K | 573.54K | 1.32M | |
| Operating Income | -- | -5.07M | -1.15M | -2.13M | -1.04M | -1.76M | |
| EBITDA | -- | -5.07M | -1.10M | -2.06M | -989.69K | -1.72M | |
| Pretax Income | -- | -5.07M | -1.10M | -2.06M | -990.95K | -1.72M | |
| Net Income | -- | -5.07M | -1.10M | -2.06M | -990.95K | -1.72M | |
| EPS Diluted | -0.07 | -0.17 | -0.03 | -- | -0.03 | -0.79 | |
| Diluted Shares | 29.76M | 30.01M | 32.40M | -- | 34.38M | 60.84M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--